ArticleBreast cancer (Dove Medical Press)2026
RNA-Binding Protein CSTF2 Drives Immune Evasion and Malignant Progression in Breast Cancer by Degrading THSD1 mRNA.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Resistance to immunotherapy in breast cancer (BC) is intimately connected to the dynamic tumor immunoediting process. RNA-binding proteins (RBPs) are recognized as pivotal modulators of BC advancement. Cleavage stimulation factor 2 (CSTF2), a core factor involved in mRNA 3'-end maturation, shows significant overexpression in numerous cancers and is correlated with adverse clinical outcomes. However, the precise molecular mechanisms through which it drives malignancy by regulating immunoediting remain incompletely understood. Methods: This study performed a systematic evaluation of CSTF2's expression profile and prognostic significance in BC using data from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). CSTF2 expression was modulated via knockdown and overexpression approaches to study core malignant traits, such as proliferative capacity and cell migration. The role of CSTF2 in immunoediting was examined through immune landscape analysis and flow cytometry. Results: Integrated bioinformatics identified a regulatory pathway whereby CSTF2 induces transcriptional upregulation of the immune checkpoint molecule programmed death-ligand 1 (PD-L1) by promoting degradation of thrombospondin type-1 domain-containing protein 1 (THSD1) mRNA. The consequent increase in PD-L1 expression potently inhibits CD8⁺ T cell-mediated tumoricidal activity, thereby facilitating immune escape and collectively accelerating malignant progression in BC. Conclusion: This study delineates the detailed molecular mechanisms by which the RBP CSTF2 exacerbates malignant progression, offering fresh theoretical insights and potential targets for targeted immunotherapeutic strategies in BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.